---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-195560"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:37:11.622613+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# UroGen raises $120M from institutions; UGN-102 Phase 3 trials meet endpoints

## Summary
- $120M gross proceeds from private placement at $9.54/share led by RA Capital and Great Point Partners.
- ATLAS trial: UGN-102 reduced risk of recurrence/progression/death by 55% vs TURBT alone.
- ENVISION trial: 79.2% complete response rate at 3 months for UGN-102.
- Pre-funded warrants at $0.001/share, not expiring; closing expected July 28.
- NDA submission for UGN-102 anticipated in 2024 pending additional data.

## SEC filing metadata
- accession: 0001193125-23-195560
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312523195560/0001193125-23-195560-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312523195560/d538950d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-195560
- JSON: https://secwatch.observer/filing/0001193125-23-195560.json
- Plain text: https://secwatch.observer/filing/0001193125-23-195560.txt

## Key facts
- Material Agreements
  UroGen Pharma Ltd. entered into Securities Purchase Agreement with certain institutional and other accredited investors valued at $120.0 million (effective 2023-07-26).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain institutional and other accredited investors
  - Value: $120.0 million
  - Effective: 2023-07-26
  source text: On July 26, 2023, UroGen Pharma Ltd., an Israeli company (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue to the Purchasers 12,579,156 ordinary shares of the Company (“Shares”) (or in lieu of Shares, pre-funded warrants to purchase ordinary shares of the Company) at a purchase price of $9.54 per Share (or $9.539 for each ordinary share underlying a pre-funded warrant), in a private placement transaction (the “Private Placement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312523195560/0001193125-23-195560-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.